What's happening
This bill prohibits businesses from selling xylazine to individuals without proof of legitimate use or to anyone under 21.
Why it matters
Targets public health and safety concerns. By restricting xylazine sales to only those with legitimate institutional, veterinary, or scientific purposes, the bill aims to prevent the drug’s diversion for illicit or unsafe use, which has been linked to dangerous side effects and its growing presence in the illicit drug supply.
Establishes robust compliance requirements. Businesses must not only verify and document the age and intended use of purchasers but also retain these records, increasing accountability and creating a paper trail that could assist in enforcement and investigations.
Imposes meaningful financial penalties. Significant civil penalties for violations ($3,000 for a first offense; $6,500 for subsequent offenses) serve as a deterrent to businesses considering noncompliant sales, indicating the seriousness of the regulatory effort.
Directs penalty revenue to drug treatment and education. Funds collected from violations are earmarked for the state’s drug treatment and public education fund, potentially supporting efforts to combat substance misuse and educate the public on the risks associated with drugs like xylazine.
Albany, before your first meeting.
Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.
Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.
Headline styles
Ban Xylazine Sales
Plain English, a few words. Used as the page title.
Sponsors
31 Co-sponsors
- John Zaccaro Jr.
- George Alvarez
- Charles Lavine
- Jenifer Rajkumar
- Manny De Los Santos
- Tony Simone
- Karines Reyes
- Michaelle C. Solages
- Inez E. Dickens
- Jonathan Rivera
- Philip Ramos
- Juan Ardila
- Marianne Buttenschon
- Phara Souffrant Forrest
- MaryJane Shimsky
- Nikki Lucas
- Brian Cunningham
- Catalina Cruz
- Jo Anne Simon
- Nader Sayegh
- Harvey Epstein
- Rodneyse Bichotte Hermelyn
- Alex Bores
- Michael Tannousis
- Mike Reilly
- Keith Brown
- Jake Ryan Blumencranz
- Lester Chang
- Jodi Giglio
- Samuel Pirozzolo
- Joe DeStefano
History
- Recommitted to consumer protection
- Returned to senate
- Repassed assembly
- Amended on third reading 6506b
- Vote reconsidered - restored to third reading
- Returned to assembly
- Recalled from senate
- Referred to consumer protection
- Delivered to senate
- Passed assembly
- Ordered to third reading cal.186
- Returned to assembly
Show 12 earlier actions
- Died in senate
- Referred to consumer protection
- Delivered to senate
- Passed assembly
- Ordered to third reading rules cal.380
- Rules report cal.380
- Reported
- Reported referred to rules
- Print number 6506a
- Amend and recommit to codes
- Reported referred to codes
- Referred to consumer affairs and protection
Companion bill
The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.
Ban Xylazine Sales
In Senate Committee · Consumer Protection · Sponsor Nathalia Fernandez
Full text
2 pagesUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗
STATE OF NEW YORK
6506--B Cal. No. 186
2023-2024 Regular Sessions
IN ASSEMBLY
April 12, 2023
Introduced by M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, RAJKUMAR, DE LOS SANTOS, SIMONE, REYES, SOLAGES, DICKENS, RIVERA, RAMOS, ARDILA, BUTTENSCHON, FORREST, SHIMSKY, LUCAS, CUNNINGHAM, CRUZ, SIMON, SAYEGH, EPSTEIN, BICHOTTE HERMELYN, BORES, TANNOUSIS,… Show allHide
Introduced by M. of A. TAPIA, ZACCARO, ALVAREZ, LAVINE, RAJKUMAR, DE LOS SANTOS, SIMONE, REYES, SOLAGES, DICKENS, RIVERA, RAMOS, ARDILA, BUTTENSCHON, FORREST, SHIMSKY, LUCAS, CUNNINGHAM, CRUZ, SIMON, SAYEGH, EPSTEIN, BICHOTTE HERMELYN, BORES, TANNOUSIS, REILLY, K. BROWN, BLUMENCRANZ, CHANG, J. A. GIGLIO, PIROZZOLO, DeSTEFANO -- read once and referred to the Committee on Consumer Affairs and Protection -reported and referred to the Committee on Codes -- committee discharged, bill amended, ordered reprinted as amended and recommitted to said committee -- ordered to a third reading -- advanced to a third reading, passed by Assembly and delivered to the Senate, recalled from the Senate, vote reconsidered, bill amended, ordered reprinted, retaining its place on the order of third reading
AN ACT to amend the general business law, in relation to prohibiting the sale of xylazine
The People of the State of New York, represented in Senate and Assembly, do enact as follows:
Section 1. The general business law is amended by adding a new section 392-k to read as follows:
§ 392-k. Sale of xylazine. 1. For purposes of this section, the term "xylazine" shall mean a pharmaceutical drug used for sedation, anesthesia, muscle relaxation, and analgesia in animals such as horses, cattle, and other non-human mammals.
2. No corporation, partnership, limited liability company, firm, online platform, or any other business entity doing business within this state shall knowingly sell, offer for sale, or deliver xylazine to individuals without proof of its intended use for institutional, veterinary, or scientific purposes.
3. No corporation, partnership, limited liability company, firm, online platform, or other business entity doing business within this state shall knowingly sell, offer for sale, or deliver xylazine to individuals under the age of twenty-one.
EXPLANATION--Matter in italics (underscored) is new; matter in brackets
[ ] is old law to be omitted.
LBD10463-07-4
4. Any corporation, partnership, limited liability company, firm, online platform or other business entity doing business within this state which knowingly sells, offers for sale, or distributes xylazine, shall require and retain sales records, proof of age, and proof of use from all purchasers.
5. Any corporation, partnership, limited liability company, firm, online platform, or other business entity doing business within this state that violates the provisions of this section by knowingly selling, offering for sale, or delivering xylazine shall be subject to a civil penalty of not more than three thousand dollars for a first violation, and sixty-five hundred dollars for each subsequent violation, recoverable in an action by the attorney general of the state of New York. All funds collected or received by the state from civil penalties imposed under this section shall be deposited in the New York state drug treatment and public education fund established pursuant to section ninetynine-jj of the state finance law.
§ 2. This act shall take effect immediately.
Reflowed for reading: line numbers and page breaks removed. Cite the official text.
Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.